0001622244 false 12-31 0001622244 2021-11-23 2021-11-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 23, 2021  

 

One World Products, Inc.
(Exact name of registrant as specified in charter)

 

Nevada

  333-200529  

61-1744826

(State or other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3471 West Oquendo Road, Suite 301 Las Vegas, NV

  89118
(Address of principal executive offices)   (zip code)

 

Registrant’s telephone number, including area code: (800) 605-3201

 

One World Pharma, Inc.

 

(Former name or form former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

 

On November 23, 2021, One World Pharma, Inc. (the “Company”) changed its name to One World Products, Inc. through the merger of One World Products, Inc., a recently formed Nevada corporation wholly-owned by the Company, with and into the Company (the “Name Change Merger”) pursuant to the applicable provisions of the Nevada Revised Statutes (“NRS”). As permitted by the NRS, the articles of merger filed with the Secretary of State of the state of Nevada to effect the Name Change Merger amended Article I of the Company’s Articles of Incorporation to change the Company’s name to “One World Products, Inc.”

 

The Name Change Merger was effected pursuant to an Agreement and Plan of Merger dated October 11, 2021, which has been filed as Exhibit 2.1 to this Current Report on Form 8-K, and which is incorporated herein by reference. The Name Change Merger was effected solely to effect the change of the Company’s name, and had no effect on our officers, directors, operations, assets or liabilities.

 

The Name Change Merger was approved by the Financial Industry Regulatory Authority (“FINRA”) on November 30, 2021 and will become effective in the marketplace at the open of business on December 1, 2021.

 

(d) Exhibits.

 

Exhibit 2.1   Agreement and Plan of Merger dated October 11, 2021, between One World Pharma, Inc. and One World Products, Inc.
     
Exhibit 3.1   Articles of Merger Pursuant to NRS 92A.200 as filed with the Nevada Secretary of State on November 23, 2021
     
Exhibit 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  One World Pharma, Inc.
   
  Date: November 30, 2021
     
  By: /s/ Vahe Gabriel
  Name: Vahe Gabriel
  Title: Chief Financial Officer

 

 

 

 

 

 

Exhibit 2.1

 

AGREEMENT AND PLAN OF MERGER

 

This AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated this 11th day of October, 2021, by and between One World Pharma, Inc., a Nevada corporation (“OW Pharma”), and One World Products, Inc., a Nevada corporation and a wholly-owned subsidiary of OW Pharma (“OW Products”), is made with respect to the following facts.

 

RECITALS

 

WHEREAS, OW Pharma is a corporation duly organized and existing under the laws of the State of Nevada;

 

WHEREAS, OW Products is a corporation duly organized and existing under the laws of the State of Nevada;

 

WHEREAS, the board of directors of OW Products has approved the plan of merger embodied in this Agreement; and

 

WHEREAS, the board of directors of OW Pharma has approved the plan of merger embodied in this Agreement.

 

NOW THEREFORE, in consideration of the mutual agreements and covenants set forth herein, the parties hereto do hereby agree to merge on the terms and conditions herein provided, as follows:

 

ARTICLE I

MERGER

 

1.1 The Merger. Upon the terms and subject to the conditions hereof, on the Effective Date (as hereinafter defined), OW Products shall be merged with and into OW Pharma in accordance with the applicable laws of the State of Nevada (the “Merger”). The separate existence of OW Products shall cease, and OW Pharma shall be the surviving corporation under the name “One World Products, Inc.” (as renamed, the “Surviving Corporation”) and shall be governed by the laws of the State of Nevada.

 

1.2 The Effective Date. The Merger shall become effective on the date and at the time (the “Effective Date”) that:

 

(a) the Articles of Merger, in substantially the form previously circulated among the Boards of Directors of OW Pharma and OW Products, that the parties hereto intend to deliver to the Secretary of State of the State of Nevada, are accepted and declared effective by the Secretary of State of the State of Nevada; and

 

(b) after satisfaction of the requirements of the laws of the State of Nevada.

 

1.3 Articles of Incorporation. On the Effective Date, the Articles of Incorporation of OW Pharma, as in effect immediately prior to the Effective Date, shall continue in full force and effect as the Articles of Incorporation of the Surviving Corporation except that Article 1 of the Articles of Incorporation of OW Pharma, as the Surviving Corporation, shall be amended to state that the name of the corporation is “One World Products, Inc.”.

 

1.4 Bylaws. On the Effective Date, the Bylaws of OW Pharma, as in effect immediately prior to the Effective Date, shall continue in full force and effect as the bylaws of the Surviving Corporation.

 

1.5 Directors and Officers. The directors and officers of OW Pharma immediately prior to the Effective Date shall be the directors and officers of the Surviving Corporation, until their successors shall have been duly elected and qualified or until otherwise provided by law, the Articles of Incorporation of the Surviving Corporation or the Bylaws of the Surviving Corporation.

 

 

 

 

ARTICLE II

CANCELLATION OF SHARES

 

Upon the Effective Date, by virtue of the Merger and without any action on the part of the holder thereof, each share of common stock of OW Products, par value of $0.001 per share, issued and outstanding immediately prior to the Effective Date shall be cancelled.

 

ARTICLE III

EFFECT OF THE MERGER

 

3.1 Rights, Privileges, Etc. On the Effective Date of the Merger, the Surviving Corporation, without further act, deed or other transfer, shall retain or succeed to, as the case may be, and possess and be vested with all the rights, privileges, immunities, powers, franchises and authority, of a public as well as of a private nature, of OW Products and OW Pharma; all property of every description and every interest therein, and all debts and other obligations of or belonging to or due to each of OW Products and OW Pharma on whatever account shall thereafter be taken and deemed to be held by or transferred to, as the case may be, or invested in the Surviving Corporation without further act or deed; title to any real estate, or any interest therein vested in OW Products or OW Pharma, shall not revert or in any way be impaired by reason of this merger; and all of the rights of creditors of OW Products and OW Pharma shall be preserved unimpaired, and all liens upon the property of OW Products or OW Pharma shall be preserved unimpaired, and all debts, liabilities, obligations and duties of the respective corporations shall thenceforth remain with or be attached to, as the case may be, the Surviving Corporation and may be enforced against it to the same extent as if all of said debts, liabilities, obligations and duties had been incurred or contracted by it.

 

3.2 Further Assurances. From time to time, as and when required by the Surviving Corporation or by its successors and assigns, there shall be executed and delivered on behalf of OW Products such deeds and other instruments, and there shall be taken or caused to be taken by it such further other action, as shall be appropriate or necessary in order to vest or perfect in or to confirm of record or otherwise in the Surviving Corporation the title to and possession of all the property, interest, assets, rights, privileges, immunities, powers, franchises and authority of OW Products and otherwise to carry out the purposes of this Agreement, and the officers and directors of the Surviving Corporation are fully authorized in the name and on behalf of OW Products or otherwise to take any and all such action and to execute and deliver any and all such deeds and other instruments.

 

ARTICLE IV

GENERAL

 

4.1 Abandonment. This Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time, by mutual written agreement of OW Products and OW Pharma.

 

4.2 Amendment. At any time prior to the Effective Date, this Agreement may be amended or modified in writing by the board of directors of both OW Products and OW Pharma.

 

4.3 Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Nevada.

 

4.4 Counterparts. In order to facilitate the filing and recording of this Agreement, the same may be executed in any number of counterparts, each of which shall be deemed to be an original.

 

4.5 Electronic Means. Delivery of an executed copy of this Agreement by electronic facsimile transmission or other means of electronic communication capable of producing a printed copy will be deemed to be execution and delivery of this Agreement as of the date hereof.

 

2

 

 

IN WITNESS WHEREOF, the undersigned has executed this Agreement and Plan of Merger, effective as of this 11th day of October, 2021.

 

  One World Pharma, Inc., a Nevada corporation
     
  By: /s/ Vahe Gabriel
  Name: Vahe Gabriel
  Title: Chief Financial Officer
     
     
  One World Products, Inc., a Nevada corporation
     
  By: /s/ Vahe Gabriel
  Name: Vahe Gabriel
  Title: President

 

3

 

 

 

 

Exhibit 3.1